RU2522976C2 - Профилактика и лечение патологических состояний глаз, вызванных комплементом - Google Patents

Профилактика и лечение патологических состояний глаз, вызванных комплементом Download PDF

Info

Publication number
RU2522976C2
RU2522976C2 RU2009147744/10A RU2009147744A RU2522976C2 RU 2522976 C2 RU2522976 C2 RU 2522976C2 RU 2009147744/10 A RU2009147744/10 A RU 2009147744/10A RU 2009147744 A RU2009147744 A RU 2009147744A RU 2522976 C2 RU2522976 C2 RU 2522976C2
Authority
RU
Russia
Prior art keywords
antibody
factor
binding fragment
antigen binding
amd
Prior art date
Application number
RU2009147744/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2009147744A (ru
Inventor
Филип ХАСС
Цзяньпин ИНЬ
Кеннет Мл КАТШКЕ
Миках СТЕФФЕК
Кристиан ВИСМАНН
ЛОКЕРЕН КАМПАГНЕ Менно ВАН
Original Assignee
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39638868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2522976(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дженентек, Инк. filed Critical Дженентек, Инк.
Publication of RU2009147744A publication Critical patent/RU2009147744A/ru
Application granted granted Critical
Publication of RU2522976C2 publication Critical patent/RU2522976C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
RU2009147744/10A 2007-05-23 2008-05-22 Профилактика и лечение патологических состояний глаз, вызванных комплементом RU2522976C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US93979107P 2007-05-23 2007-05-23
US60/939,791 2007-05-23
PCT/US2008/064526 WO2008147883A1 (en) 2007-05-23 2008-05-22 Prevention and treatment of complement-associated eye conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2014113046/10A Division RU2014113046A (ru) 2007-05-23 2014-04-03 Профилактика и лечение патологических состояний глаз, вызванных комплементом

Publications (2)

Publication Number Publication Date
RU2009147744A RU2009147744A (ru) 2011-06-27
RU2522976C2 true RU2522976C2 (ru) 2014-07-20

Family

ID=39638868

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2009147744/10A RU2522976C2 (ru) 2007-05-23 2008-05-22 Профилактика и лечение патологических состояний глаз, вызванных комплементом
RU2014113046/10A RU2014113046A (ru) 2007-05-23 2014-04-03 Профилактика и лечение патологических состояний глаз, вызванных комплементом

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2014113046/10A RU2014113046A (ru) 2007-05-23 2014-04-03 Профилактика и лечение патологических состояний глаз, вызванных комплементом

Country Status (28)

Country Link
US (6) US8007791B2 (enExample)
EP (1) EP2152755B1 (enExample)
JP (4) JP5416695B2 (enExample)
KR (1) KR101540126B1 (enExample)
CN (3) CN104367999A (enExample)
AR (1) AR066660A1 (enExample)
AU (1) AU2008256835B2 (enExample)
BR (1) BRPI0811142A8 (enExample)
CA (1) CA2683498A1 (enExample)
CL (1) CL2008001498A1 (enExample)
CY (1) CY1116062T1 (enExample)
DK (1) DK2152755T3 (enExample)
ES (1) ES2533242T3 (enExample)
HK (1) HK1207327A1 (enExample)
HR (1) HRP20150281T1 (enExample)
IL (2) IL201476A (enExample)
MX (1) MX2009012422A (enExample)
PE (1) PE20090294A1 (enExample)
PH (1) PH12013500992B1 (enExample)
PL (1) PL2152755T3 (enExample)
PT (1) PT2152755E (enExample)
RS (1) RS53901B1 (enExample)
RU (2) RU2522976C2 (enExample)
SG (1) SG10201401404RA (enExample)
SI (1) SI2152755T1 (enExample)
TW (2) TWI419704B (enExample)
WO (1) WO2008147883A1 (enExample)
ZA (1) ZA200907028B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4764590B2 (ja) * 2000-04-29 2011-09-07 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 黄班変性関連疾患の診断および治療
SG10201804008UA (en) * 2005-11-04 2018-06-28 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
TW201716437A (zh) 2006-11-02 2017-05-16 建南德克公司 人類化之抗-因子ｄ抗體及其用途
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
JP5564045B2 (ja) * 2008-09-02 2014-07-30 ノバルティス アーゲー 二環式キナーゼ阻害剤
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
AU2010208046B2 (en) 2009-01-29 2014-10-02 Forsight Vision4, Inc. Posterior segment drug delivery
CA2761310C (en) * 2009-05-07 2017-02-28 Charles S. Craik Antibodies and methods of use thereof
US20110165648A1 (en) * 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
CN103209664A (zh) 2010-08-05 2013-07-17 弗赛特影像4股份有限公司 可植入的治疗装置
BR112013010769A2 (pt) 2010-11-01 2019-09-24 Genentech Inc predição de progressão para degeneração macular relacionada à idade avançada usando um escore poligênico
PT2661433T (pt) 2011-01-04 2017-10-24 Novartis Ag Compostos de indole ou seus análogos úteis para o tratamento da degeneração macular relacionada com a idade (amd)
US9540443B2 (en) 2011-01-26 2017-01-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
WO2014002058A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
ES2644700T3 (es) 2012-06-28 2017-11-30 Novartis Ag Derivados de pirrolidina y su uso como moduladores de la ruta del complemento
CN104379579B (zh) 2012-06-28 2017-03-08 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
US9815819B2 (en) 2012-06-28 2017-11-14 Novartis Ag Complement pathway modulators and uses thereof
EP2867225B1 (en) 2012-06-28 2017-08-09 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
CA2882724A1 (en) 2012-07-12 2014-01-16 Novartis Ag Complement pathway modulators and uses thereof
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
US9255155B2 (en) 2013-01-31 2016-02-09 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of treating cancer
CN105246438B (zh) 2013-03-28 2018-01-26 弗赛特影像4股份有限公司 用于输送治疗物质的眼科植入物
SG11201601044XA (en) 2013-08-12 2016-03-30 Genentech Inc Compositions and method for treating complement-associated conditions
WO2015054298A1 (en) * 2013-10-07 2015-04-16 Massachusetts Eye And Ear Infirmary Methods of preventing or reducing photoreceptor cell death
US20160339008A1 (en) * 2013-10-25 2016-11-24 Children's Medical Center Corporation Methods of treating or preventing vascular diseases of the retina
AU2015253042A1 (en) 2014-05-01 2016-10-20 Genentech, Inc. Anti-factor D antibody variants and uses thereof
CN113975386A (zh) 2014-05-23 2022-01-28 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
JP6853257B2 (ja) * 2015-09-23 2021-03-31 サンガモ セラピューティクス， インコーポレイテッド Ｈｔｔリプレッサー及びその使用
US10407510B2 (en) * 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
CN108513585A (zh) 2015-10-30 2018-09-07 豪夫迈·罗氏有限公司 测量因子d活性和因子d抑制剂效力的方法
MY196448A (en) 2015-10-30 2023-04-12 Genentech Inc Anti-Htra1 Antibodies and Methods of use Thereof
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
KR20180091097A (ko) * 2015-12-23 2018-08-14 그리노파티온 바이오테크 게엠베하 보체 활성화를 억제하기 위한 폴리펩티드
WO2017127761A1 (en) 2016-01-20 2017-07-27 Vitrisa Therapeutics, Inc. Compositions and methods for inhibiting factor d
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
AU2018217720A1 (en) * 2017-02-10 2019-09-05 The Trustees Of The University Of Pennsylvania Anti-factor D antibodies and uses thereof
CN109632924B (zh) * 2018-12-17 2022-02-08 上海市第一人民医院 人黄斑新生血管性疾病的血浆脂质标记物及其应用
WO2021009778A2 (en) * 2019-07-18 2021-01-21 Pandorum Technologies Private Limited Methods for culturing mesenchymal stem cells, products thereof, and applications thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2232991C1 (ru) * 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Способ определения функциональной активности фактора d комплемента человека

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620915B2 (en) * 1993-12-23 2003-09-16 Icos Corporation Monoclonal antibodies specific for integrin α-d subunit
WO2001004311A1 (en) 1999-07-07 2001-01-18 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2002008284A2 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2002000690A2 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US20050197285A1 (en) * 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US6472520B2 (en) * 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
US8007798B2 (en) * 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US7282565B2 (en) * 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7419663B2 (en) * 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) * 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
ATE410512T1 (de) 1997-11-21 2008-10-15 Genentech Inc Plättchen-spezifische antigene und deren pharmazeutische verwendung
AU2577799A (en) 1998-02-09 1999-08-23 Human Genome Sciences, Inc. 45 human secreted proteins
JP4437192B2 (ja) * 1998-02-20 2010-03-24 タノックス インコーポレイテッド 補体活性化阻害剤
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
ES2312205T3 (es) 1998-03-10 2009-02-16 Genentech, Inc. Nuevo polipeptido y acidos nucleicos que lo codifican.
AU5587799A (en) 1998-08-27 2000-03-21 Incyte Pharmaceuticals, Inc. Protein transport-associated molecules
CA2348757A1 (en) 1998-12-16 2000-06-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000037025A2 (en) * 1998-12-21 2000-06-29 Ludwig Institute For Cancer Research Antibodies to truncated vegf-d and uses thereof
ES2327785T3 (es) 1998-12-22 2009-11-03 Genentech, Inc. Procedimientos y compuestos para inhibir el crecimiento de celulas neoplasticas.
CA2362427A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP4836329B2 (ja) 1999-03-11 2011-12-14 メルク セローノ エス．エイ． 血管接着分子およびその機能の調節
US6642353B1 (en) * 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
UA72943C2 (uk) 1999-11-02 2005-05-16 Ульяновскій Государствєнний Тєхніческій Унівєрсітєт Спосіб очищення рідини від феромагнітних частинок (варіанти) і пристрій для його здійснення (варіанти)
EP1234030A4 (en) 1999-11-19 2003-05-07 Human Genome Sciences Inc 18 HUMANE SECRETIED PROTEINS
CA2491433A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2003258714A1 (en) 2002-09-06 2004-03-29 Cytos Biotechnology Ag Immune modulatory compounds and methods
WO2006071856A2 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
SG10201804008UA (en) * 2005-11-04 2018-06-28 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
TW201716437A (zh) * 2006-11-02 2017-05-16 建南德克公司 人類化之抗-因子ｄ抗體及其用途
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
JP4349447B2 (ja) 2007-07-19 2009-10-21 トヨタ自動車株式会社 インバータ制御装置および車両

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2232991C1 (ru) * 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Способ определения функциональной активности фактора d комплемента человека

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PETRUKHIN K., "New therapeutic targets in atrophic age-related macular degeneration." Expert Opin Ther Targets. (2007); 11(5):625-39. UNDAR A. et al., "Novel Anti-Factor D Monoclonal Antibody Inhibits Complement and Leukocyte Activation in a Baboon Model of Cardiopulmonary Bypass." Ann Thorac Surg (2002);74:355-62. *

Also Published As

Publication number Publication date
CA2683498A1 (en) 2008-12-04
US20130052685A1 (en) 2013-02-28
IL201476A0 (en) 2010-05-31
BRPI0811142A8 (pt) 2018-12-18
US20090181017A1 (en) 2009-07-16
US8268310B2 (en) 2012-09-18
EP2152755B1 (en) 2014-12-31
DK2152755T3 (en) 2015-03-02
PT2152755E (pt) 2015-04-01
JP2014087346A (ja) 2014-05-15
EP2152755A1 (en) 2010-02-17
US20130302333A1 (en) 2013-11-14
RS53901B1 (sr) 2015-08-31
JP2016145205A (ja) 2016-08-12
SG10201401404RA (en) 2014-08-28
KR20100033973A (ko) 2010-03-31
PH12013500992B1 (en) 2018-12-14
HK1139161A1 (en) 2010-09-10
PL2152755T3 (pl) 2015-06-30
CY1116062T1 (el) 2017-02-08
CL2008001498A1 (es) 2009-06-12
IL248552A0 (en) 2016-12-29
WO2008147883A1 (en) 2008-12-04
JP5416695B2 (ja) 2014-02-12
HRP20150281T1 (hr) 2015-04-10
RU2014113046A (ru) 2015-10-10
IL201476A (en) 2016-11-30
CN101754980A (zh) 2010-06-23
SI2152755T1 (sl) 2015-05-29
TWI419704B (zh) 2013-12-21
CN104367999A (zh) 2015-02-25
CN107096029B (zh) 2021-02-26
ES2533242T3 (es) 2015-04-08
PE20090294A1 (es) 2009-03-27
US20180079826A1 (en) 2018-03-22
AR066660A1 (es) 2009-09-02
JP2017197577A (ja) 2017-11-02
US20160272726A1 (en) 2016-09-22
WO2008147883A8 (en) 2013-05-23
TW201417829A (zh) 2014-05-16
MX2009012422A (es) 2009-12-04
US20110282034A1 (en) 2011-11-17
AU2008256835A1 (en) 2008-12-04
CN107096029A (zh) 2017-08-29
RU2009147744A (ru) 2011-06-27
US8007791B2 (en) 2011-08-30
CN101754980B (zh) 2014-10-29
ZA200907028B (en) 2010-12-29
HK1207327A1 (en) 2016-01-29
TW200904471A (en) 2009-02-01
JP2010528047A (ja) 2010-08-19
KR101540126B1 (ko) 2015-07-28
PH12013500992A1 (en) 2016-01-25
AU2008256835B2 (en) 2013-08-01
BRPI0811142A2 (pt) 2014-12-23
US8497094B2 (en) 2013-07-30

Similar Documents

Publication Publication Date Title
RU2522976C2 (ru) Профилактика и лечение патологических состояний глаз, вызванных комплементом
JP5980249B2 (ja) 補体が関係している障害の予防および処置のためのｃ３ｂ抗体ならびに方法
US20180037667A1 (en) Anti-factor b antibodies and their uses
AU2017254945A1 (en) Prevention and treatment of complement-associated eye conditions
AU2013213753A1 (en) Prevention and treatment of complement-associated eye conditions
HK1139161B (en) Prevention and treatment of complement- associated eye conditions

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20190523